课题基金 / 基金详情

项目摘要

项目成果

Daniel E. Goldberg的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT Malaria afflicts several hundred million and kills more than 600,000 people each year, mostly children in Sub-Saharan Africa. Aspartic proteases have long been antimalarial targets of interest. A large number of aspartic protease inhibitors that are potent against parasites in culture have been developed, but their specific targets have been elusive. Plasmepsin X (PMX) is one of the least characterized aspartic proteases found in asexual intraerythrocytic malaria parasites. We have recently found that PMX is a key enzyme for intraerythrocytic parasite egress and invasion. It activates the master trigger subtilysin-like protease 1 (SUB1), launching proteolytic events that allow merozoites to get out of the host red blood cell (RBC) and invade fresh RBCs. We have identified a class of aspartic protease inhibitors called aminohydantoins that appear to kill parasites through PMX blockade, preventing SUB1 activation and impairing egress/invasion. PMX knockdown phenocopies inhibitor action. One of the inhibitors has favorable pharmacokinetic properties and gives oral cure in a rodent malaria model. We believe that PMX is an exciting new drug target but need to better characterize its function to inform ongoing drug development and enhance our understanding of parasite biology. To address these questions, aim 1 will examine the specificity of PMX and will address the question of whether SUB1 maturation by PMX is direct. Biochemical assays using isolated PMX with SUB1 as a substrate and with a random peptide library will be performed. Aim 2 will focus on what PMX interacts with. Is SUB1 the only substrate? What else is in the secretory vesicle called the exoneme, where PMX and SUB1 both reside? Aim 3 will address the question of how PMX itself gets activated. Our preliminary data suggest that there must be an upstream enzyme. We will characterize the processing and look for a maturase. We anticipate that the proposed studies will yield great insight into the pathogenesis of malaria and will point the way to new therapies for this devastating disease.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41467-022-32271-7
发表时间: 2022-08-04
期刊: NATURE COMMUNICATIONS
影响因子: 16.6
作者: [Mukherjee, Sumit, Nguyen, Suong, Sharma, Eashan, Goldberg, Daniel E.]
通讯作者: Goldberg, Daniel E.
DOI: 10.1128/mbio.00673-23
发表时间: 2023-04-25
期刊: MBIO
影响因子: 6.4
作者: [Mukherjee, Sumit, Nasamu, Armiyaw S., Rubiano, Kelly C., Goldberg, Daniel E.]
通讯作者: Goldberg, Daniel E.
DOI: 10.1111/cmi.12868
发表时间: 2018-10
期刊: Cellular microbiology
影响因子: 3.4
作者: [Glushakova S, Beck JR, Garten M, Busse BL, Nasamu AS, Tenkova-Heuser T, Heuser J, Goldberg DE, Zimmerberg J]
通讯作者: Zimmerberg J
Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins, Inhibit Malaria Infection at Multiple Life Stages.
针对疟疾天冬氨酰蛋白酶、纤溶酶的速效小分子可抑制多个生命阶段的疟疾感染。
DOI: 10.1021/acsinfecdis.8b00197
发表时间: 2019
期刊: ACS infectious diseases
影响因子: 5.3
作者: [Singh,Snigdha, Rajendran,Vinoth, He,Jiang, Singh,AmitK, Achieng,AngelaO, Vandana, Pant,Akansha, Nasamu,ArmiyawS, Pandit,Mansi, Singh,Jyoti, Quadiri,Afshana, Gupta,Nikesh, Poonam, Ghosh,PrahladC, Singh,BrajendraK, Narayanan,Latha, Kempai]
通讯作者: Kempai
Specificity of Plasmodium falciparum protein export
  • 批准号:
    10632093
  • 项目类别:
  • 资助金额:
    $19.46万
  • 财政年份:
    2022
  • 负责人:
    Daniel E. Goldberg
  • 依托单位:
Defining the resistome in P. falciparum: evolution and mechanism
Specificity of Plasmodium falciparum protein export
  • 批准号:
    10508060
  • 项目类别:
  • 资助金额:
    $23.63万
  • 财政年份:
    2022
  • 负责人:
    Daniel E. Goldberg
  • 依托单位:
Structural Vaccinology and Design of Novel Imunogens for Malaria Vaccine Development
  • 批准号:
    10330551
  • 项目类别:
  • 资助金额:
    $71.36万
  • 财政年份:
    2018
  • 负责人:
    Daniel E. Goldberg
  • 依托单位:
海外基金